Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

Compare

509 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRNX Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Crinetics

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$74.00

▲(124.17%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $74.00 with a high forecast of $97.00 and a low forecast of $53.00. The average price target represents a 124.17% change from the last price of $33.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","98":"$98","46.25":"$46.3","63.5":"$63.5","80.75":"$80.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,46.25,63.5,80.75,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.52,38.403076923076924,43.28615384615385,48.16923076923077,53.05230769230769,57.93538461538461,62.818461538461534,67.70153846153846,72.58461538461538,77.4676923076923,82.35076923076923,87.23384615384614,92.11692307692307,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.52,36.63384615384616,39.74769230769231,42.861538461538466,45.97538461538462,49.089230769230774,52.20307692307692,55.316923076923075,58.43076923076923,61.54461538461538,64.65846153846154,67.77230769230769,70.88615384615385,{"y":74,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.52,35.018461538461544,36.51692307692308,38.01538461538462,39.51384615384616,41.012307692307694,42.510769230769235,44.00923076923077,45.50769230769231,47.00615384615385,48.504615384615384,50.003076923076925,51.50153846153846,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.05,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$97.00

Average Price Target$74.00

Lowest Price Target$53.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Hold

-3.06%

Downside

Reiterated

06/03/25

Crinetics Pharmaceuticals has a moderate overall score due to financial challenges, including persistent losses and cash flow issues. Positive earnings call sentiment and strategic growth plans provide some optimism, but the technical analysis and valuation highlight ongoing financial risks. The company's ability to execute on its strategic initiatives, particularly the launch of paltusotine, will be crucial for improving its financial health.

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$81

Buy

145.38%

Upside

Reiterated

05/30/25

Crinetics Pharmaceuticals: Promising Pipeline and Strategic Positioning Justify Buy Rating

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$60

Buy

81.76%

Upside

Reiterated

05/27/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Stifel Nicolaus

Yasmeen RahimiPiper Sandler

Piper Sandler

$97

Buy

193.85%

Upside

Reiterated

05/21/25

Piper Sandler Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)

Maxwell SkorMorgan Stanley

Morgan Stanley

$70→$65

Buy

96.91%

Upside

Reiterated

05/13/25

Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position

Joseph SchwartzLeerink Partners

Leerink Partners

$80

Buy

142.35%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Veracyte (NASDAQ: VCYT) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$82

Buy

148.41%

Upside

Reiterated

05/09/25

Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Crinetics Pharmaceuticals: Promising Outlook with Paltusotine Approval and Strategic Market Positioning

Jessica FyeJ.P. Morgan

J.P. Morgan

$57→$53

Buy

60.56%

Upside

Reiterated

03/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

202.94%

Upside

Reiterated

02/28/25

Crinetics (CRNX) PT Raised to $100 at Cantor FitzgeraldCantor Fitzgerald analyst Josh Schimmer raised the price target on Crinetics (NASDAQ: CRNX) to $100.00 (from $90.00) while maintaining a Overweight rating.

Jonathan WollebenCitizens JMP

Citizens JMP

$92→$91

Buy

175.67%

Upside

Reiterated

02/28/25

Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials

David LebowitzCiti

Citi

$74→$68

Buy

106.00%

Upside

Reiterated

02/28/25

Crinetics Pharmaceuticals: Buy Rating Backed by Promising Pipeline and Strategic Growth Plans

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Initiated

02/03/25

Crinetics initiated with a Peer Perform at Wolfe ResearchCrinetics initiated with a Peer Perform at Wolfe Research

Dennis DingJefferies

Jefferies

$55

Buy

66.62%

Upside

Upgraded

01/21/25

Jefferies upgrades Crinetics (CRNX) to BuyJefferies analyst Dennis Ding upgraded Crinetics (NASDAQ: CRNX) from Hold to Buy with a price target of $55.00.

Leland GershellOppenheimer

Oppenheimer

$73

Buy

121.15%

Upside

Reiterated

01/13/25

Oppenheimer Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Hold

-3.06%

Downside

Reiterated

06/03/25

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$81

Buy

145.38%

Upside

Reiterated

05/30/25

Crinetics Pharmaceuticals: Promising Pipeline and Strategic Positioning Justify Buy Rating

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$60

Buy

81.76%

Upside

Reiterated

05/27/25

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Stifel Nicolaus

Yasmeen RahimiPiper Sandler

Piper Sandler

$97

Buy

193.85%

Upside

Reiterated

05/21/25

Piper Sandler Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)

Maxwell SkorMorgan Stanley

Morgan Stanley

$70→$65

Buy

96.91%

Upside

Reiterated

05/13/25

Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position

Joseph SchwartzLeerink Partners

Leerink Partners

$80

Buy

142.35%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Veracyte (NASDAQ: VCYT) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$82

Buy

148.41%

Upside

Reiterated

05/09/25

Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating

Tyler Van BurenTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Crinetics Pharmaceuticals: Promising Outlook with Paltusotine Approval and Strategic Market Positioning

Jessica FyeJ.P. Morgan

J.P. Morgan

$57→$53

Buy

60.56%

Upside

Reiterated

03/26/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$90→$100

Buy

202.94%

Upside

Reiterated

02/28/25

Jonathan WollebenCitizens JMP

Citizens JMP

$92→$91

Buy

175.67%

Upside

Reiterated

02/28/25

Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials

David LebowitzCiti

Citi

$74→$68

Buy

106.00%

Upside

Reiterated

02/28/25

Crinetics Pharmaceuticals: Buy Rating Backed by Promising Pipeline and Strategic Growth Plans

Andy ChenWolfe Research

Wolfe Research

―

Hold

―

Initiated

02/03/25

Crinetics initiated with a Peer Perform at Wolfe ResearchCrinetics initiated with a Peer Perform at Wolfe Research

Dennis DingJefferies

Jefferies

$55

Buy

66.62%

Upside

Upgraded

01/21/25

Jefferies upgrades Crinetics (CRNX) to BuyJefferies analyst Dennis Ding upgraded Crinetics (NASDAQ: CRNX) from Hold to Buy with a price target of $55.00.

Leland GershellOppenheimer

Oppenheimer

$73

Buy

121.15%

Upside

Reiterated

01/13/25

Oppenheimer Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+12.70%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +12.70% per trade.

3 Months

xxx

Success Rate

11/12 ratings generated profit

Average Return

+24.05%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 91.67% of your transactions generating a profit, with an average return of +24.05% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

12/20 ratings generated profit

Average Return

+35.73%

reiterated a buy rating 10 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +35.73% per trade.

2 Years

xxx

Success Rate

18/29 ratings generated profit

Average Return

+61.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.07% of your transactions generating a profit, with an average return of +61.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRNX has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 74.00.

Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.10 with a range of -$1.22 to -$0.94. The previous quarter’s EPS was -$1.04. CRNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $680.00K with a range of $0.00 to $5.14M. The previous quarter’s sales results were $361.00K. CRNX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 74.00.

What is CRNX’s upside potential, based on the analysts’ average price target?

Crinetics Pharmaceuticals has 124.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRNX a Buy, Sell or Hold?

Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Crinetics Pharmaceuticals’s price target?

The average price target for Crinetics Pharmaceuticals is 74.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $97.00 ,the lowest forecast is $53.00. The average price target represents 124.17% Increase from the current price of $33.01.

What do analysts say about Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CRNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

CRNX Analyst Ratings

CRNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crinetics Pharmaceuticals

CRNX Analyst Recommendation Trends

CRNX Financial Forecast

CRNX Earnings Forecast

CRNX Sales Forecast

CRNX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts